Within Eucor, Uni Basel coordinates the focus area personalized health / precision medicine. By fostering and establishing collaborations between French, German and Swiss universities or university clinics, this initiative also aims at developing standards for data-driven health research across political borders.

PHB supports the establishment and implementation of clinical and translational data interface/integration (data sharing platform) across borders strengthening Uni Basel and the Upper Rhine region as leading centres in the field of personalized health and health-related data research.

 

CLINNOVA is a cross-border initiative bringing together leading academic and clinical institutions within the EUCOR network and Luxembourg.

This quadrinational initiative aims to support the digitalization of healthcare and precision medicine. CLINNOVA focuses on three chronic inflammatory autoimmune diseases, multiple sclerosis (MS), rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). By creating performant, interoperable data-enabling environment, CLINNOVA intends to improve patient care, accelerate biomedical research and nucleate business opportunities through an increase in patient-oriented application.

The objectives are to establish:

• A network of world-class multidisciplinary translational research centers focused on chronic inflammatory autoimmune diseases.
• Prospective patient cohorts and a federated biobanking strategy allowing to achieve standardized collection and processing of biological samples in the different institutions.
• A platform for innovation in digital health based on interoperable data infrastructures established in the different institutions.
• A federated artificial intelligence platform to enable algorithm training on a large amount of multi-dimensional data across borders in a secure, interoperable and transparent manner, thereby generating personalized therapy solutions for patients.

Through its unique and innovative approach, CLINNOVA creates considerable impact for patient, society, academic and clinical research, and industry. Ultimately, CLINNOVA contributes directly to improving lives of patients with autoimmune diseases.